Impact of Nirsevimab Immunization on Pediatric Hospitalization Rates: A Systematic Review and Meta-Analysis (2024) DOI Creative Commons
Matteo Riccò, Antonio Cascio,

Silvia Corrado

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(6), P. 640 - 640

Published: June 8, 2024

A systematic review with a meta-analysis was performed to gather available evidence on the effectiveness of monoclonal antibody nirsevimab in prevention lower respiratory tract diseases (LRTDs) due syncytial virus (RSV) children and newborns (CRD42024540669). Studies reporting real-world experience randomized controlled trials (RCTs) were searched for three databases (PubMed, Embase, Scopus) until 1 May 2024. Our analysis included five RCTs, seven reports, one official report from health authorities. Due cross-reporting RCTs inclusion multiple series single study, 45,238 infants 19 series. The documented pooled immunization efficacy 88.40% (95% confidence interval CI) 84.70 91.21) occurrence hospital admission RSV, moderate heterogeneity (I2 24.3%, 95% CI 0.0 56.6). Immunization decreased overall length observation time (Spearman’s r = −0.546, p 0.016), risk breakthrough infections substantially greater studies times ≥150 days compared lasting <150 (risk ratio 2.170, 1.860 2.532). However, effect meta-regression conflicting (β 0.001, −0.001 0.002; 0.092). In conclusion, delivery quite effective preventing admissions LRTDs. further analyses whole RSV season are required before tailoring specific public interventions.

Language: Английский

Impact of Nirsevimab Immunization on Pediatric Hospitalization Rates: A Systematic Review and Meta-Analysis (2024) DOI Creative Commons
Matteo Riccò, Antonio Cascio,

Silvia Corrado

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(6), P. 640 - 640

Published: June 8, 2024

A systematic review with a meta-analysis was performed to gather available evidence on the effectiveness of monoclonal antibody nirsevimab in prevention lower respiratory tract diseases (LRTDs) due syncytial virus (RSV) children and newborns (CRD42024540669). Studies reporting real-world experience randomized controlled trials (RCTs) were searched for three databases (PubMed, Embase, Scopus) until 1 May 2024. Our analysis included five RCTs, seven reports, one official report from health authorities. Due cross-reporting RCTs inclusion multiple series single study, 45,238 infants 19 series. The documented pooled immunization efficacy 88.40% (95% confidence interval CI) 84.70 91.21) occurrence hospital admission RSV, moderate heterogeneity (I2 24.3%, 95% CI 0.0 56.6). Immunization decreased overall length observation time (Spearman’s r = −0.546, p 0.016), risk breakthrough infections substantially greater studies times ≥150 days compared lasting <150 (risk ratio 2.170, 1.860 2.532). However, effect meta-regression conflicting (β 0.001, −0.001 0.002; 0.092). In conclusion, delivery quite effective preventing admissions LRTDs. further analyses whole RSV season are required before tailoring specific public interventions.

Language: Английский

Citations

14